Clinical Trial Update: Effect of Empagliflozin on Metabolic Outcomes in Adults Living With HIV Receiving Dolutegravir-Based Therapy [Phase 2]

View source ↗

Summary

This Phase 2 trial is evaluating the metabolic effects of empagliflozin in adults with HIV on dolutegravir-based therapy; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection
• Metabolic Syndrome
• Obesity

Drugs mentioned

• Dolutegravir (dolutegravir)
• Empagliflozin (empagliflozin)

Snippet

Sponsor: Abdelrahman Mahmoud | Conditions: Metabolic Syndrome, Obesity & Overweight | Phase 2 | Status: RECRUITING